Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.

about

Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.

Item

http://www.wikidata.org/entity/Q49925457

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Long-term efficacy and safety ...... with undetectable viral load.

@en

Long-term efficacy and safety ...... with undetectable viral load.

@nl

type

Item

label

Long-term efficacy and safety ...... with undetectable viral load.

@en

Long-term efficacy and safety ...... with undetectable viral load.

@nl

prefLabel

Long-term efficacy and safety ...... with undetectable viral load.

@en

Long-term efficacy and safety ...... with undetectable viral load.

@nl

P1476

Long-term efficacy and safety ...... with undetectable viral load.

@en

P2093

Alba Bigoloni

http://www.w3.org/2001/XMLSchema#string

Andrea Poli

http://www.w3.org/2001/XMLSchema#string

Daniela Mancusi

http://www.w3.org/2001/XMLSchema#string

Elisabetta Carini

http://www.w3.org/2001/XMLSchema#string

Giuseppe Tambussi

http://www.w3.org/2001/XMLSchema#string

Laura Galli

http://www.w3.org/2001/XMLSchema#string

Nicola Gianotti

http://www.w3.org/2001/XMLSchema#string

Roberta Termini

http://www.w3.org/2001/XMLSchema#string

Silvia Nozza

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE Studies.

Recent advances in rilpivirine: new data and promising treatment option.

Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine single-tablet regimen in virologically suppressed HIV-positive patients on stable antiretroviral therapy.

The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy: Meta-analysis.

Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity.

Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.

Initiation of rilpivirine, tenofovir and emtricitabine (RPV/TDF/FTC) regimen in 363 patients with virological vigilance assessment in 'real life'.

Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.

P304

e0191300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0191300

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonella Castagna

Adriano Lazzarin

Nadia Galizzi

P577

2018-02-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29451870

http://www.w3.org/2001/XMLSchema#string

P921

viral load

P932

5815573

http://www.w3.org/2001/XMLSchema#string